Physician profile
Laura E Frado
NPI 1487946166
$8,681.70
in general payments reported to CMS, 2019-2025
25 companies · $3,511 in 2025
The $3,511 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $1,090 · 2023: $1,531 · 2024: $2,129 · 2025: $3,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,811.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,641.10 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,322.02 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $1,139.48 | 2021-2024 | Zeposia |
| Pfizer INC. | $498.11 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $429.67 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $322.89 | 2024-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $287.80 | 2022-2024 | Dificid |
| Lilly USA, LLC | $250.14 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $158.30 | 2022-2025 | Sucraid, Sucraid |
| Exact Sciences Corporation | $119.95 | 2024-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $105.54 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $83.50 | 2021-2023 | Suflave, Sutab |
| Ardelyx, INC. | $82.30 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $79.78 | 2025 | Rezdiffra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.59 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $59.14 | 2023-2025 | Clenpiq, Rebyota |
| Genzyme Corporation | $44.13 | 2024-2025 | |
| Vivus LLC | $38.06 | 2024 | Qsymia |
| Celltrion USA INC. | $27.28 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $24.30 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $22.80 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $20.13 | 2023 | |
| Evoke Pharma, INC. | $19.30 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Frado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.